Catalyst Event
AbbVie Inc (ABBV) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
6/2/2026, 12:00:00 AM
The European Commission approved AQUIPTA (atogepant) for the acute treatment of migraine in adults on 2026-06-02; analysts forecast this market expansion will result in a price impact of ≥5% expected.
Korean Translation
2026-06-02 유럽연합 집행위원회의 아큅타(atogepant) 편두통 급성 치료제 승인 및 적응증 확대가 이루어졌으며, 분석가들은 시장 확대에 따른 주가 영향이 5% 이상일 것으로 예상됨.
Related Recent Events
Alphabet Inc (GOOGL) · Earnings Release
Alphabet Q2 2026 earnings release scheduled for July 22, 2026, with analysts forecasting EPS of approximately $2.85-$2.87 forecasted.
7/22/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Other
Alphabet held its 2026 Annual Meeting of Shareholders on June 5, 2026. Proposals included an increase to the 2021 Stock Plan share reserve.
6/5/2026, 12:00:00 AM
Hims & Hers Health Inc (HIMS) · Other
Hims & Hers appointed Dr. Anant Vinjamoori as its new Chief Medical Officer on 2026-06-04, which resulted in a 7.23% stock price increase.
6/4/2026, 12:00:00 AM
Natera Inc (NTRA) · Other
Announced a strategic collaboration with CytoDyn to use its ctDNA platform to support CytoDyn's metastatic colorectal cancer development program.
6/4/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
Announced on 2026-06-03 plans to halve its €2.3 billion investment in a new German plant; medium impact estimated due to regulatory headwinds and reduced growth capacity, expected.
6/3/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Other
The UK's Competition & Markets Authority (CMA) announced on June 3, 2026, new conduct requirements for Google's AI-powered search, giving publishers more control over their content.
6/3/2026, 12:00:00 AM